Placental tissue grafts and improved methods of preparing and using the same
US-2016030633-A1 · Feb 4, 2016 · US
US11219647B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11219647-B2 |
| Application number | US-201816164191-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 18, 2018 |
| Priority date | Feb 14, 2011 |
| Publication date | Jan 11, 2022 |
| Grant date | Jan 11, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described herein are compositions composed of micronized placental components and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions are also described herein.
Opening claim text (preview).
What is claimed: 1. A micronized composition comprising micronized particles, said micronized particles comprising an amnion layer and a chorion layer; wherein the chorion layer is layered directly over the amnion layer; wherein the amnion layer has an epithelial layer; and wherein an intermediate layer of said amnion layer has been substantially removed. 2. The micronized composition of claim 1 , further comprising micronized amnion. 3. The micronized composition of claim 1 , further comprising one or more additional layers selected from the group consisting of amnion, chorion, intermediate tissue layer, allograft pericardium, allograft acellular dermis, Wharton's jelly, purified xenograft Type-I collagen, biocellulose polymers or copolymers, biocompatible synthetic polymer or copolymer films, purified small intestinal submucosa, bladder acellular matrix, cadaveric fascia, and any combination thereof. 4. The micronized composition of claim 1 , wherein the micronized particles are dehydrated. 5. The micronized composition of claim 1 , wherein the micronized particles are less than 500 μm. 6. The micronized composition of claim 1 , wherein the micronized particles are from 150 μm to 350 μm. 7. The micronized composition of claim 1 , wherein the micronized particles are from 25 μm to 150 μm. 8. The micronized composition of claim 1 , wherein the micronized particles are from 25 μm to 75 μm. 9. A sterile pharmaceutical composition comprising a pharmaceutically acceptable fluid carrier and micronized particles, said micronized particles comprising an amnion layer and a chorion layer; wherein the chorion layer is layered directly over the amnion layer; wherein the amnion layer has an epithelial layer; and wherein an intermediate layer of said amnion layer has been substantially removed. 10. The sterile pharmaceutical composition of claim 9 , wherein the pharmaceutically acceptable fluid carrier comprises water, aqueous hyaluronic acid, saline, Ringer's solution, dextrose solution, Hank's solution, a buffer, or an nonaqueous vehicle. 11. The sterile pharmaceutical composition of claim 10 , wherein the buffer comprises a phosphate buffer, bicarbonate buffer, or Tris buffer. 12. The sterile pharmaceutical composition of claim 9 , wherein the composition is injectable. 13. The sterile pharmaceutical composition of claim 9 , wherein the composition is a liquid, gel or paste. 14. The sterile pharmaceutical composition of claim 9 , wherein the micronized particles are dehydrated. 15. The sterile pharmaceutical composition of claim 9 , wherein the micronized particles are less than 500 μm. 16. The sterile pharmaceutical composition of claim 9 , wherein the micronized particles are from 150 μm to 350 μm. 17. The sterile pharmaceutical composition of claim 9 , wherein the micronized particles are from 25 μm to 150 μm. 18. The sterile pharmaceutical composition of claim 9 , wherein the micronized particles are from 25 μm to 75 μm.
characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel · CPC title
Flowable or injectable implant compositions · CPC title
for soft tissue reconstruction · CPC title
characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this (A61L27/3687, A61L27/3691 take precedence) · CPC title
for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.